Table 2. Factors associated with the presence of INSTI DRMs in antiretroviral treatment-naïve HIV-1-infected patients.
| Presence of INSTI DRM (including minor mutationsa) | Present (n = 13) | Absent (n = 93) | P value |
|---|---|---|---|
| Sex (male) | 13 (100.0) | 92 (98.9) | > 0.99 |
| Age, yr | 31 (25–42) | 34 (28–44) | 0.528 |
| Initial CD4 T-cell count, cells/mm3 | 349 (112–428) | 292 (181–440) | 0.950 |
| Initial HIV RNA viral load, copies/mL | 43,020 (3,285–380,815) | 40,712 (11,511–133,525) | 0.751 |
| Treatment failure within 1 year | 0/11 (0.0) | 0/88 (0.0) | 1.000 |
| HIV RNA copies < 40 copies/mL after 1 year | 7/7 (100) | 49/53 (92.5) | 1.000 |
| Increase in CD4 T-cell count after 1 year of ART, cells/mm3 | 294 (149–468) | 302 (192–369) | 0.833 |
| Presence of RTI mutations (including minor mutations) | 6/13 (46.2) | 26/90 (28.9) | 0.217 |
| Presence of PI mutations (including minor mutations) | 9/13 (69.2) | 61/90 (67.8) | 1.000 |
Data are presented as No. (%) or median (interquartile range).
INSTI = integrase strand transfer inhibitor, DRM = drug resistance mutation, HIV = human immunodeficiency virus, ART = antiretroviral therapy, RTI = reverse transcriptase inhibitor, PI = protease inhibitor.
aMinor mutations included accessory mutations and polymorphisms.